Key result
Growth hormone replacement therapy in GH-deficient adults should be initiated at a low dose and titrated individually based on clinical response, body composition, quality of life, and IGF-I levels.
Why the study?
Does Growth hormone (GH) replacement therapy improve body composition and quality of life in GH-deficient adults?
Does Growth hormone (GH) replacement therapy improve body composition and quality of life in GH-deficient adults?
Growth hormone replacement therapy in GH-deficient adults should be initiated at a low dose and titrated individually based on clinical response, body composition, quality of life, and IGF-I levels.
Answers are grounded in this paper and cite their sources.
May support individualized low-dose GH titration in deficient adults; leaves open confirmation by prospective RCTs.
Growth hormone (GH) replacement therapy in GH-deficient adults should be initiated with a low dose, independent of body weight or body surface area. Measurements of serum insulin-like growth factor I (IGF-I) concentrations, as well as clinical examinations aimed at detecting signs of fluid excess, are important as safety markers to avoid overtreatment with GH. At present, there is no optimal marker for the long-term efficacy of GH replacement therapy. The long-term maintenance dose of GH should, therefore, be titrated in each individual based on the clinical response, with the aim of normalizing body hydration, other measurements of body composition, quality of life and well-being, and biochemical indices such as serum IGF-I concentration.
No takes yet. Share an insight, caveat, or question.
Svensson et al. (2001) conducted a review in Growth hormone deficiency. Growth hormone (GH) replacement therapy was evaluated. Growth hormone replacement therapy in GH-deficient adults should be initiated at a low dose and titrated individually based on clinical response, body composition, quality of life, and IGF-I levels.
Synapse has enriched 10 related papers. Consider them for comparative context: